Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. (Nasdaq: GH) is a precision oncology company that regularly issues news about its blood and tissue tests, real-world data initiatives, and AI analytics in cancer care. This news page aggregates company announcements, press releases, and other updates so readers can follow how Guardant’s technologies are being used in screening, monitoring, and treatment selection for cancer.
Recent Guardant Health news has covered topics such as preliminary financial results and test volumes, payer coverage milestones for the Shield blood test for colorectal cancer screening, and collaborations aimed at expanding access to oncology clinical trials. The company also reports on scientific presentations that highlight the performance of Guardant Reveal for minimal residual disease detection and therapy response monitoring, and Guardant360 Liquid for multiomic profiling and breast cancer subtyping.
Guardant’s updates frequently describe how its tests are applied across all stages of care, including early detection, recurrence monitoring, and advanced cancer management. News items also include information about partnerships with hospitals and research centers, participation in healthcare and investor conferences, and initiatives related to data infrastructure and AI-ready environments for large-scale genomic datasets.
Investors, clinicians, researchers, and others interested in Guardant Health can use this page to review the company’s latest press releases and historical announcements. By browsing this feed, readers can see how Guardant’s portfolio of liquid biopsy and precision oncology diagnostics is being deployed in clinical practice, research collaborations, and broader efforts to improve access to cancer screening and personalized treatment.
Guardant Health (Nasdaq: GH) has announced a strategic partnership with LabFlorida/SunDx Labs to expand access to Guardant Shield™, the first FDA-approved blood test for colorectal cancer (CRC) screening, to senior living communities. Through this agreement, LabFlorida will be the exclusive distributor for Shield across senior living facilities in Florida.
The partnership aims to address a critical healthcare gap, as up to 71% of assisted living residents are not current with CRC screening. Shield offers a simple blood draw alternative to traditional screening methods, targeting the 1-2 million individuals in senior living communities who are at increased risk of colorectal cancer due to age. The test could significantly improve screening rates for this vulnerable population, where CRC is the second leading cause of cancer-related deaths with a 91% five-year survival rate if detected early.
Guardant Health (Nasdaq: GH) has announced a strategic partnership with PathGroup to expand the reach of its FDA-approved Shield™ blood test for colorectal cancer (CRC) screening. The collaboration will extend Shield's availability to over 250 hospitals and health systems across 25 states, reaching more than 15,000 PathGroup-affiliated physicians.
Shield, the first FDA-approved blood test for CRC primary screening, will be integrated into PathGroup's electronic ordering systems, streamlining the workflow for healthcare providers. The partnership leverages PathGroup's extensive network of phlebotomists and Patient Service Centers, serving over 5 million patients annually. Additionally, PathGroup will provide expertise in immunohistochemistry (IHC) testing for Guardant's comprehensive biomarker testing suite.
Guardant Health (NASDAQ:GH) announced positive clinical validation results for its Shield™ V2 blood test algorithm for colorectal cancer (CRC) screening. The test demonstrated 84% overall sensitivity with 90% specificity for CRC detection. Stage-specific sensitivities were: 62% for stage I, 100% for stage II, 96% for stage III, and 100% for stage IV.
The validation was conducted using an expanded cohort from the 20,000+ person ECLIPSE study. Shield, which recently received NCCN guideline inclusion as the first FDA-approved blood test for primary CRC screening, showed 13% sensitivity in detecting advanced adenomas. The company is also developing a multi-cancer detection test that received FDA Breakthrough Device Designation.
Guardant Health (Nasdaq: GH), a precision oncology company, has announced an upcoming Investor Day scheduled for September 24, 2025, in New York City. The event will begin at 9:00 a.m. ET / 6:00 a.m. PT and will feature presentations from the company's leadership team.
While in-person attendance is by invitation only due to limited capacity, interested parties can access both live and archived webcasts of the presentation through the "Investors" section of Guardant Health's website at www.guardanthealth.com.
Guardant Health (NASDAQ:GH), a precision oncology company, announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The company's management will engage in a fireside chat on September 8th at 4:05 p.m. ET. Investors can access both live and archived webcasts of the presentation through the investor relations section of Guardant Health's website.
Guardant Health (Nasdaq: GH) announced the approval of equity grants to new non-executive employees under its 2023 Employment Inducement Incentive Award Plan. The grants include 239,565 restricted stock units (RSUs) awarded to 189 employees and stock options to purchase 23,542 shares granted to two employees.
The RSUs will vest over three years, with one-third vesting annually. The stock options, priced at $41.42 per share, will vest one-third after one year, with remaining shares vesting monthly over 24 months. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements.
Guardant Health (NASDAQ: GH) has announced a strategic partnership with the American Cancer Society (ACS) to expand cancer screening access and promote health equity. The collaboration aims to support ACS's nationwide screening initiatives, including the I Love You, Get Screened campaign, which reached over 313 million impressions in 2024.
The partnership focuses on addressing screening disparities in California, where mammogram screening rates (64%) and colorectal cancer screening rates (60%) lag behind national averages. In 2024, these initiatives resulted in over 555,000 completed screenings and 7,800 cancers detected. The program will provide patient education, screening navigation, transportation support, and language access services to underserved communities.
Guardant Health (Nasdaq: GH), a precision oncology company, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference in Boston. The company's management will engage in a fireside chat on August 13th at 9:30 a.m. ET. Investors and interested parties can access both live and archived webcasts of the presentation through the investor relations section of Guardant Health's website.
Guardant Health (Nasdaq: GH) reported strong Q2 2025 financial results, with total revenue reaching $232.1 million, representing a 31% year-over-year increase. The company raised its 2025 revenue guidance to $915-925 million, projecting 24-25% growth.
Key performance metrics include: Oncology revenue of $158.7M (+22%), Screening revenue of $14.8M with 16,000 Shield tests, and Biopharma & Data revenue of $56M (+28%). The company achieved a non-GAAP gross margin of 66%, up from 60% in Q2 2024.
Notable developments include the introduction of 11 Smart Liquid Biopsy applications for Guardant360 Liquid, Shield's inclusion in NCCN guidelines, and FDA Breakthrough Device Designation for Shield Multi-Cancer Detection. The company expects to reach free cash flow breakeven in Q4 2025 for non-Screening business.
Guardant Health (NASDAQ: GH) has partnered with actor James Van Der Beek to promote awareness about colorectal cancer (CRC) screening and their FDA-approved Shield blood test. Van Der Beek, who was diagnosed with stage 3 CRC at age 46, is speaking publicly for the first time about the importance of screening.
The Shield blood test, approved by the FDA last year, offers a convenient screening option for adults 45+ at average risk for CRC through a simple blood draw. With CRC being the second most deadly cancer in the U.S., causing over 50,000 deaths annually, early detection is crucial as the five-year survival rate exceeds 90% when caught early but drops to 13% in late stages.
The National Comprehensive Cancer Network has included Shield in its updated CRC screening guidelines, potentially improving patient access. This advancement is significant as more than 50 million Americans avoid traditional screening methods due to their unpleasant or inconvenient nature.